Genomic Study Maps Shared Risk Factors for 14 Psychiatric Disorders
December 14, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Opana
Synonyms :
oxymorphone
Class :
Opioid Analgesics
Brand Name :
Opana
Synonyms :
oxymorphone
Class :
Opioid Analgesics
Dosage Forms & Strengths
Immediate release (tablet): Schedule II
5 mg
10 mg
Extended release (tablet): Schedule II
Moderate to severe pain
5 mg, 15 mg, 20 mg, 30 mg;
7.5 mg, 10 mg, 40 mg
Patients who have not previously taken opioids (immediate release): 10 to 20 mg taken orally every 4 to 6 hours as required at first, and then adjusted as necessary.
Extended-release tablet initial dosing Patients who have not previously taken opioids or do not have a tolerance: should begin with a dose of 5 mg administered orally every 12 hours. The dosage should then be adjusted gradually in increments of 5 to 10 mg after every 3 to 7 days until a level is reached that effectively relieves pain while minimizing any potential adverse effects Patients who have developed tolerance to opioids: Patients who have been taking a minimum dosage of 60 mg/day orally for morphine, 25 mcg/hr transdermal fentanyl, 30 mg/day orally for oxycodone, 8 mg/day orally for hydromorphone, 25 mg/day orally for oxymorphone, or an equivalent amount of another opioid for a period of one week or more.
Dosage Forms & Strengths
Safety and efficacy not determined
Refer to adult dosing
may have an increased Effect of CNS depressant when combined with serotonergic opioids
it increases the effect of CNS depressants
CNS depressants increase the effect of paraldehyde
CNS depressants increase the CNS depressing effect of thalidomide
CNS depressants increase the effect of flunarizine
it increases the effect of CNS depressants
may reduce the analgesic effect of Opioid agonists
may reduce the analgesic effect of Opioid agonists
may reduce the analgesic effect of Opioid agonists
may reduce the analgesic effect of Opioid agonists
It may enhance sedation when combined with a shepherd's purse
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
When encainide is used together with oxymorphone, this leads to a reduction in the encainide’s metabolism
lofexidine may enhance the CNS depressant effect of CNS depressants
may increase the CNS depressant effect
may enhance the activity
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the sedative effect of CNS depressants
may increase the CNS depressant effect
it increases the effect of CNS depressants
Actions and Spectrum:
It is an opioid analgesic used to treat moderate to severe pain by attaching to central nervous system receptors. Its main action is analgesic but it can cause negative side effects like respiratory depression and drowsiness.
Frequency defined
1-10%
Somnolence (9%)
Constipation (4%)
Pruritus (8%)
Confusion (3%)
Headache (7%)
Dizziness (7%
Vomiting (9%)
1 to <10%
cardiac disorders: tachycardia
Gastrointestinal disorders: abdominal distention, dry mouth and flatulence
Respiratory, thoracic and mediastinal disorders: hypoxia
Vascular disorders: hypotension
General disorders and administration site conditions: sweating increased
Nervous system disorders: sedation and anxiety
<1%
Agitation
CNS depression
Hot flashes
Urticaria
Weakness
Dehydration
Dermatitis
Mental impairment
Visual disturbances
Mental status changes
Insomnia
Weight decreased
Miosis
Dyspepsia
Respiratory rate decreased
Oxygen saturation decreased
Difficult micturition
Urinary retention
Vision blurred
Depressed level of consciousness
Disorientation
Restlessness
Allergic reactions
Respiratory depression
Respiratory distress
Euphoric mood
Hallucination
Appetite decreased
Bradycardia
Lethargy
Fatigue
Depression
Palpitation
Postural hypotension
Hypersensitivity
Clamminess
Flushing
Nervousness
Syncope
Dyspnea
Dysphoria
Edema
Feeling jittery
Abdominal pain
Ileus
Diarrhea
Post marketing reports
Nervous system disorder: convulsion, memory impairment, Amnesia
Anaphylaxis
Adrenal insufficiency: Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use
Immune system disorders: other hypersensitivity reactions and angioedema
Androgen deficiency: Cases of androgen deficiency have occurred with chronic use of opioids
Serotonin syndrome: Cases of serotonin syndrome, have been reported during concomitant use of opioids with serotonergic drugs, a potentially life-threatening condition
>10%
Pyrexia (14%)
Nausea (19%)
Black Box Warning
Overdose leads to death and likely respiratory depression
Contraindication/Caution:
Oxymorphone is contraindicated for individuals with intolerance to its ingredients, respiratory depression, gastrointestinal blockage, or severe bronchial asthma.
Pregnancy warnings:
Pregnancy category: N/A
Lactation: Excretion into human milk is unknown
Pregnancy Categories:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
Category B: There were lack of studies on pregnant women and no evidence of risk to the foetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology
Oxymorphone reduces pain perception and promotes well-being by attaching to mu, delta, and kappa receptors.
Pharmacodynamics
Oxymorphone actions are on the central nervous system specifically mu, delta, and kappa opioid receptors. Its potency is high due to its strong affinity for these receptors.
Pharmacokinetics
Absorption
Efficiently absorbed
Distribution
oxymorphone has a strong affinity for albumin and other proteins.
Metabolism
Cytochrome P450 enzymes also break down oxymorphone.
Elimination and excretion
Elimination half-life is around 7 to 9 hours.
Administration:
Oxymorphone comes in various forms including immediate-release and extended-release pills which are typically taken every 4 to 6 hours to manage pain.
Patient information leaflet
Generic Name: oxymorphone
Why do we use oxymorphone?
Oxymorphone is a strong opioid analgesic used to manage moderate to severe pain in adults including those who suffering from chronic illnesses like cancer, surgery, and trauma.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
